Neil Blumberg

Summary

Affiliation: University of Rochester
Country: USA

Publications

  1. pmc The platelet as an immune cell-CD40 ligand and transfusion immunomodulation
    Neil Blumberg
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, NY 14642, USA
    Immunol Res 45:251-60. 2009
  2. pmc Hospital variation in transfusion and infection after cardiac surgery: a cohort study
    Mary A M Rogers
    Division of General Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
    BMC Med 7:37. 2009
  3. ncbi request reprint Association of ABO-mismatched platelet transfusions with morbidity and mortality in cardiac surgery
    N Blumberg
    Department of Pathology, University of Rochester Medical Center, Rochester, New York 14642, USA
    Transfusion 41:790-3. 2001
  4. ncbi request reprint Deleterious clinical effects of transfusion immunomodulation: proven beyond a reasonable doubt
    Neil Blumberg
    Transfusion Medicine Unit, Department of Pathology and Laboratory Medicine, University of Rochester Medical Center and Strong Memorial Hospital, Rochester, New York 14642, USA
    Transfusion 45:33S-39S; discussion 39S-40S. 2005
  5. ncbi request reprint An association of soluble CD40 ligand (CD154) with adverse reactions to platelet transfusions
    Neil Blumberg
    Transfusion Medicine Unit and Clinical Laboratories, Department of Pathology and Laboratory Medicine, Hematology Oncology Unit, The University of Rochester Medical Center, Rochester, New York 14642, USA
    Transfusion 46:1813-21. 2006
  6. ncbi request reprint The intention-to-treat principle in clinical trials and meta-analyses of leukoreduced blood transfusions in surgical patients
    Neil Blumberg
    University of Rochester Medical Center, Rochester, New York 14642, USA
    Transfusion 47:573-81. 2007
  7. ncbi request reprint Decreased sepsis related to indwelling venous access devices coincident with implementation of universal leukoreduction of blood transfusions
    Neil Blumberg
    Transfusion Medicine Unit, Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York 14642, USA
    Transfusion 45:1632-9. 2005
  8. ncbi request reprint WBC reduction of RBC transfusions is associated with a decreased incidence of RBC alloimmunization
    Neil Blumberg
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center and Strong Memorial Hospital, Rochester, New York 14642, USA
    Transfusion 43:945-52. 2003
  9. pmc An association between decreased cardiopulmonary complications (transfusion-related acute lung injury and transfusion-associated circulatory overload) and implementation of universal leukoreduction of blood transfusions
    Neil Blumberg
    Transfusion Medicine Unit, and the Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York 14642, USA
    Transfusion 50:2738-44. 2010
  10. pmc 15-deoxy-delta12,14-PGJ2 enhances platelet production from megakaryocytes
    Jamie J O'Brien
    Department of Environmental Medicine and the Lung Biology and Disease Program, University of Rochester, NY, USA
    Blood 112:4051-60. 2008

Collaborators

Detail Information

Publications45

  1. pmc The platelet as an immune cell-CD40 ligand and transfusion immunomodulation
    Neil Blumberg
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, NY 14642, USA
    Immunol Res 45:251-60. 2009
    ..These effects come under the rubric of transfusion immunomodulation, which postulates that transfusion recipient biology, particularly immune function, is dramatically altered by transfusion of stored allogeneic blood...
  2. pmc Hospital variation in transfusion and infection after cardiac surgery: a cohort study
    Mary A M Rogers
    Division of General Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
    BMC Med 7:37. 2009
    ..Concomitant with this re-examination have been reports showing variability in the use of specific blood components. This investigation was designed to assess hospital variation in blood use and outcomes in cardiac surgery patients...
  3. ncbi request reprint Association of ABO-mismatched platelet transfusions with morbidity and mortality in cardiac surgery
    N Blumberg
    Department of Pathology, University of Rochester Medical Center, Rochester, New York 14642, USA
    Transfusion 41:790-3. 2001
    ..The transfusion of ABO-mismatched platelets has been associated with increased morbidity and mortality during induction therapy for acute leukemia and allogeneic progenitor cell transplantation...
  4. ncbi request reprint Deleterious clinical effects of transfusion immunomodulation: proven beyond a reasonable doubt
    Neil Blumberg
    Transfusion Medicine Unit, Department of Pathology and Laboratory Medicine, University of Rochester Medical Center and Strong Memorial Hospital, Rochester, New York 14642, USA
    Transfusion 45:33S-39S; discussion 39S-40S. 2005
  5. ncbi request reprint An association of soluble CD40 ligand (CD154) with adverse reactions to platelet transfusions
    Neil Blumberg
    Transfusion Medicine Unit and Clinical Laboratories, Department of Pathology and Laboratory Medicine, Hematology Oncology Unit, The University of Rochester Medical Center, Rochester, New York 14642, USA
    Transfusion 46:1813-21. 2006
    ..PLTs are the primary source of soluble CD40 ligand (sCD40L). Engagement of the receptor for CD40L induces synthesis of proinflammatory mediators including interleukin (IL)-6, IL-8, and monocyte chemotactic protein-1 (MCP-1)...
  6. ncbi request reprint The intention-to-treat principle in clinical trials and meta-analyses of leukoreduced blood transfusions in surgical patients
    Neil Blumberg
    University of Rochester Medical Center, Rochester, New York 14642, USA
    Transfusion 47:573-81. 2007
    ..In clinical trials and meta-analyses investigating leukoreduced blood transfusions to reduce postoperative infections, the intention-to-treat principle and the scientific method have been variably applied...
  7. ncbi request reprint Decreased sepsis related to indwelling venous access devices coincident with implementation of universal leukoreduction of blood transfusions
    Neil Blumberg
    Transfusion Medicine Unit, Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York 14642, USA
    Transfusion 45:1632-9. 2005
    ..We performed a retrospective study of sepsis related to indwelling venous access devices (line related infections) before and after the July 2000 implementation of universal leukoreduction...
  8. ncbi request reprint WBC reduction of RBC transfusions is associated with a decreased incidence of RBC alloimmunization
    Neil Blumberg
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center and Strong Memorial Hospital, Rochester, New York 14642, USA
    Transfusion 43:945-52. 2003
    ..Allogeneic transfusion stimulates Th2 (humoral) immunity. A hypothesis was developed that WBC reduction, by reducing the Th2 stimulus associated with transfusions, might reduce RBC alloimmunization...
  9. pmc An association between decreased cardiopulmonary complications (transfusion-related acute lung injury and transfusion-associated circulatory overload) and implementation of universal leukoreduction of blood transfusions
    Neil Blumberg
    Transfusion Medicine Unit, and the Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York 14642, USA
    Transfusion 50:2738-44. 2010
    ..Cardiopulmonary adverse events after transfusion include transfusion-related acute lung injury (TRALI) and transfusion-associated circulatory overload (TACO), which are potentially lethal and incompletely understood...
  10. pmc 15-deoxy-delta12,14-PGJ2 enhances platelet production from megakaryocytes
    Jamie J O'Brien
    Department of Environmental Medicine and the Lung Biology and Disease Program, University of Rochester, NY, USA
    Blood 112:4051-60. 2008
    ....
  11. pmc Transfusion of cell saver salvaged blood in neonates and infants undergoing open heart surgery significantly reduces RBC and coagulant product transfusions and donor exposures: results of a prospective, randomized, clinical trial
    Jill M Cholette
    Department of Pediatrics, University of Rochester, Rochester, NY, USA
    Pediatr Crit Care Med 14:137-47. 2013
    ..To evaluate whether transfusion of cell saver salvaged, stored at the bedside for up to 24 hrs, would decrease the number of postoperative allogeneic RBC transfusions and donor exposures, and possibly improve clinical outcomes...
  12. pmc Peroxisome proliferator-activated receptor gamma and retinoid X receptor transcription factors are released from activated human platelets and shed in microparticles
    Denise M Ray
    University of Rochester Medical Center, Environmental Medicine, Rochester, New York 14642, USA
    Thromb Haemost 99:86-95. 2008
    ....
  13. pmc Alterations of platelet function and clot formation kinetics after in vitro exposure to anti-A and -B
    Majed A Refaai
    Department of Pathology and Laboratory Medicine, The James P Wilmot Cancer Center, University of Rochester, Rochester, New York 14642, USA
    Transfusion 53:382-93. 2013
    ..We present here in vitro modeling data on the functional effects of exposure of PLTs to ABO antibodies...
  14. ncbi request reprint The platelet as a therapeutic target for treating vascular diseases and the role of eicosanoid and synthetic PPARgamma ligands
    Denise M Ray
    Department of Environmental Medicine and the Lung Biology and Disease Program, University of Rochester, School of Medicine and Dentistry, Box 850, 601 Elmwood Avenue, Rochester, NY 14642, USA
    Prostaglandins Other Lipid Mediat 82:68-76. 2007
    ..PPARgamma ligand treatment may prove useful for dampening unwanted platelet activation and chronic inflammatory diseases such as cardiovascular disease...
  15. pmc An association of ABO non-identical platelet and cryoprecipitate transfusions with altered red cell transfusion needs in surgical patients
    Majed A Refaai
    Department of Pathology and Laboratory Medicine, University of Rochester, Rochester, NY, USA
    Vox Sang 101:55-60. 2011
    ..Transfusion of ABO non-identical plasma, platelets and cryoprecipitate is routine practice even though adverse effects can occur...
  16. pmc Washing red blood cells and platelets transfused in cardiac surgery reduces postoperative inflammation and number of transfusions: results of a prospective, randomized, controlled clinical trial
    Jill M Cholette
    Department of Pediatrics, University of Rochester, Rochester, NY, USA
    Pediatr Crit Care Med 13:290-9. 2012
    ..We hypothesize that washing red blood cells and platelets transfused to these patients will reduce postoperative transfusion-related immune modulation and inflammation...
  17. pmc Providing ABO-identical platelets and cryoprecipitate to (almost) all patients: approach, logistics, and associated decreases in transfusion reaction and red blood cell alloimmunization incidence
    Kelly F Henrichs
    Department of Pathology and Laboratory Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    Transfusion 52:635-40. 2012
    ..In April 2005, we implemented a policy of transfusing only ABO-identical components whenever feasible, regardless of outdating or logistic considerations...
  18. pmc Platelet transfusions: impact on hemostasis, thrombosis, inflammation and clinical outcomes
    Majed A Refaai
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
    Thromb Res 127:287-91. 2011
    ..In this review, we will briefly highlight the importance of platelet transfusion, its role in inflammatory and thrombotic transfusion reactions, and visit the most recent findings on sCD40L...
  19. pmc Isoprostane and isofuran lipid mediators accumulate in stored red blood cells and influence platelet function in vitro
    Sherry L Spinelli
    Department of Pathology and Laboratory Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York
    Transfusion 54:1569-79. 2014
    ..This study investigated RBC-derived F2 -IsoPs and IsoFs during storage and their influence on human platelets (PLTs)...
  20. pmc Platelets and megakaryocytes contain functional nuclear factor-kappaB
    Sherry L Spinelli
    Department of Environmental Medicine, Box 850, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Rochester, New York 14642, USA
    Arterioscler Thromb Vasc Biol 30:591-8. 2010
    ..We discovered that human megakaryocytes and platelets express the majority of NF-kappaB family members, including the regulatory inhibitor-kappaB (I-kappaB) and I-kappa kinase (IKK) molecules...
  21. ncbi request reprint Leukocyte-reduced transfusions in cardiac surgery results of an implementation trial
    Neil Blumberg
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, NY 14642, USA
    Am J Clin Pathol 118:376-81. 2002
    ..Implementation of leukocyte reduction may be cost neutral or cost saving in at least some settings...
  22. ncbi request reprint Aspirin resistance following pediatric cardiac surgery
    Jill M Cholette
    Department of Pediatrics, University of Rochester Medical Center 601 Elmwood Avenue Rochester, New York 14642, USA
    Thromb Res 126:200-6. 2010
    ..The primary study aim was to assess aspirin resistance in this context. Secondary aims were to evaluate (1) the relationship between elevated inflammatory markers and thrombosis and (2) aspirin's effect on these levels...
  23. pmc Transfusion immunomodulation--the case for leukoreduced and (perhaps) washed transfusions
    Katie L Lannan
    Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
    Blood Cells Mol Dis 50:61-8. 2013
    ..The present review will focus on two approaches, leukoreduction and saline washing, as means to reduce adverse transfusion outcomes...
  24. pmc Foxp3 regulates megakaryopoiesis and platelet function
    Jamie J Bernard
    Department of Environmental Medicine, University of Rochester, Rochester, NY 14642, USA
    Arterioscler Thromb Vasc Biol 29:1874-82. 2009
    ..Scurfy mice and some humans with IPEX are also thrombocytopenic. The purpose of this study was to determine whether the absence of functional Foxp3 leads to defects in megakaryocytes and platelets...
  25. ncbi request reprint Platelets as a novel target for PPARgamma ligands : implications for inflammation, diabetes, and cardiovascular disease
    Denise M Ray
    Department of Environmental Medicine and the Lung Biology and Disease Program, University of Rochester, Rochester, New York 14642, USA
    BioDrugs 20:231-41. 2006
    ..Targeting platelet PPARgamma will, therefore, be an important treatment strategy for the attenuation of chronic inflammatory processes and prevention of thrombus formation...
  26. doi request reprint Nuclear emancipation: a platelet tour de force
    Sherry L Spinelli
    Department of Pathology and Laboratory Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Sci Signal 3:pe37. 2010
    ..Our appreciation of the role of transcription factors in mammalian platelet biology is nascent but holds great promise for both understanding platelet function and translation into clinical uses...
  27. pmc The Feverfew plant-derived compound, parthenolide enhances platelet production and attenuates platelet activation through NF-κB inhibition
    Julie Sahler
    Department of Microbiology and Immunology, University of Rochester, Rochester, NY, USA
    Thromb Res 127:426-34. 2011
    ..We investigated the effect of the feverfew plant-derived compound, parthenolide on platelet production and platelet activation because of its well-studied ability to induce apoptosis or differentiation in some types of cancer...
  28. doi request reprint The transfusion dilemma--weighing the known and newly proposed risks of blood transfusions against the uncertain benefits
    Majed A Refaai
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Box 608, Rochester, NY 14642, USA
    Best Pract Res Clin Anaesthesiol 27:17-35. 2013
    ..One long-standing primary concern has been bacterial and viral contamination but recently other risks have been identified, mostly related to recipient immunomodulation and storage lesion-related changes...
  29. ncbi request reprint Human bone marrow megakaryocytes and platelets express PPARgamma, and PPARgamma agonists blunt platelet release of CD40 ligand and thromboxanes
    Filiz Akbiyik
    Box 850, Department of Environmental Medicine, University of Rochester School of Medicine and Dentistry, 601 Elmwood Ave, Rochester, NY 14642, USA
    Blood 104:1361-8. 2004
    ..This may represent a novel mechanism for treatment of inflammation, thrombosis, and vascular disease in high-risk patients...
  30. pmc Lack of significant de novo HLA allosensitization in ventricular assist device recipients transfused with leukoreduced, ABO identical blood products
    Myra Coppage
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Strong Memorial Hospital, Rochester, NY, USA
    Hum Immunol 70:413-6. 2009
    ..No patient developed broad sensitization (PRA>50%). In conclusion, The use of leukoreduced, irradiated, ABO identical blood products abrogates broad allosensitization in this highly transfused population...
  31. pmc Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer
    Alok A Khorana
    James P Wilmot Cancer Center, Department of Medicine, University of Rochester, Rochester, New York, USA
    Arch Intern Med 168:2377-81. 2008
    ..Anemia is frequent in patients with cancer, but there are concerns regarding treatment with erythropoiesis-stimulating agents. Blood transfusions are commonly used as an alternative, but with little data regarding outcomes...
  32. ncbi request reprint Optimizing platelet transfusion therapy
    Joanna Mary Heal
    Hematology Oncology Unit, Department of Medicine, University of Rochester Medical Center, 601 Elwood Avenue, Box 608, Rochester, NY 14642, USA
    Blood Rev 18:149-65. 2004
    ....
  33. pmc New frontiers in transfusion biology: identification and significance of mediators of morbidity and mortality in stored red blood cells
    Katie Grimshaw
    Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
    Transfusion 51:874-80. 2011
    ..These mediators likely play a direct role in the inflammatory and prothrombotic properties of RBC transfusions. Methods such as leukoreduction, washing of RBCs, and rejuvenation may improve the quality of RBC transfusions...
  34. ncbi request reprint Transfusion immunomodulation from a clinical perspective: an update
    Majed A Refaai
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Box 608, Rochester, NY 14642, USA
    Expert Rev Hematol 6:653-63. 2013
    ..Most important is adopting more conservative transfusion practices. Leukoreduction (proven) and plasma depletion (proposed) are other methods to significantly reduce transfusion immunomodulation and its clinical sequela...
  35. ncbi request reprint ABO incompatibility between donor and recipient and clinical outcomes in allogeneic stem cell transplantation
    James Goldman
    Department of Pathology, University of Rochester Medical Center, Box 608, 60 Elmwood Avenue, Rochester, NY 14642, USA
    Leuk Res 27:489-91. 2003
    ..Our data do not support a significant role for ABO donor-recipient matching in allogeneic stem cell transplantation...
  36. pmc Developmental changes in soluble CD40 ligand
    Jill M Cholette
    Department of Pediatrics, University of Rochester Medical Center, Rochester, New York 14642, USA
    J Pediatr 152:50-4, 54.e1. 2008
    ..To determine if soluble CD40 ligand (sCD40L; formally CD154) levels vary with age and to identify age-dependent ranges in healthy pediatric and adult populations...
  37. pmc Thy-1 expression in human fibroblast subsets defines myofibroblastic or lipofibroblastic phenotypes
    Laura Koumas
    Department of Environmental Medicine, University of Rochester, Rochester, New York 14642, USA
    Am J Pathol 163:1291-300. 2003
    ....
  38. ncbi request reprint ABO-mismatched platelet transfusions and clinical outcomes after cardiac surgery
    Neil Blumberg
    Transfusion 42:1527-8; author reply 1528-9. 2002
  39. ncbi request reprint Allogeneic blood transfusions explain increased mortality in women after coronary artery bypass graft surgery
    Mary A M Rogers
    Division of General Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109 0429, USA
    Am Heart J 152:1028-34. 2006
    ..Because allogeneic blood transfusions are more common in women and have been associated with immunomodulation, the impact of transfusion on sex differences in infection and mortality was examined...
  40. pmc Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a potential cofactor in the development of transfusion-related acute lung injury
    Samina Yasmin Khan
    Bonfils Blood Center, 717 Yosemite St, Denver, CO 80230, USA
    Blood 108:2455-62. 2006
    ..We concluded that sCD40L, which accumulates during blood component storage, has the capacity to activate adherent PMNs, causing endothelial damage and possibly TRALI in predisposed patients...
  41. ncbi request reprint The causes and treatment of reactions to platelet transfusions
    Neil Blumberg
    Transfusion 43:291-2; author reply 292. 2003
  42. ncbi request reprint Universal leukocyte reduction of blood transfusions
    Neil Blumberg
    Clin Infect Dis 45:1014-5. 2007
  43. ncbi request reprint Increased risk of infection and mortality in women after cardiac surgery related to allogeneic blood transfusion
    Mary A M Rogers
    Division of General Medicine, Department of Internal Medicine, University of Michigan, and Patient Safety Enhancement Program, VA Medical Center and University of Michigan Health System, Ann Arbor, Michigan 48109 0429, USA
    J Womens Health (Larchmt) 16:1412-20. 2007
    ..This study was conducted to assess whether allogeneic blood transfusion could partially account for this gender difference, as transfusion has been associated with immunomodulation...

Research Grants2

  1. Identification and Significance of Biologic Mediators in Red Cell Concentrates
    Richard P Phipps; Fiscal Year: 2010
    ..Our research will discover explanations for these effects, and we will devise inexpensive strategies to reduce these complications ..
  2. Identification and Significance of Biologic Mediators in Red Cell Concentrates
    Neil Blumberg; Fiscal Year: 2009
    ..Our research will discover explanations for these effects, and we will devise inexpensive strategies to reduce these complications ..